News ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
65.48 ^USD	-0.12%		-2.21%	+18.75%

Apr. 17	Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing	MT
Apr. 09	ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing	Apr. 17	MT
ANI Pharmaceuticals : Corporate Presentation - April 2024	Apr. 17	PU
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension	Apr. 09	AQ
ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension	Apr. 09	CI
ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis	Apr. 04	AQ
Ani Pharmaceuticals Insider Sold Shares Worth $1,345,000, According to a Recent SEC Filing	Apr. 03	MT
ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium	Apr. 03	AQ
ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP	Mar. 27	AQ
ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP	Mar. 27	CI
Capital One Initiates ANI Pharmaceuticals at Overweight Rating	Mar. 15	MT
ANI Pharmaceuticals : Corporate Presentation - March 2024	Mar. 12	PU
Ani Pharmaceuticals Insider Sold Shares Worth $671,700, According to a Recent SEC Filing	Mar. 12	MT
Ani Pharmaceuticals Insider Sold Shares Worth $2,630,864, According to a Recent SEC Filing	Mar. 08	MT
Ani Pharmaceuticals Insider Sold Shares Worth $456,400, According to a Recent SEC Filing	Mar. 06	MT
Ani Pharmaceuticals Insider Sold Shares Worth $330,000, According to a Recent SEC Filing	Mar. 06	MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $77 From $70, Maintains Buy Rating	Mar. 05	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $83 From $73, Maintains Buy Rating	Mar. 04	MT
Truist Securities Raises Price Target on ANI Pharmaceuticals to $80 From $72, Maintains Buy Rating	Mar. 01	MT
Sector Update: Health Care Stocks Decline Late Afternoon	Feb. 29	MT
Sector Update: Health Care Stocks Retreat Thursday Afternoon	Feb. 29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Summary

Filters